Longevity has moved far beyond a niche science idea. In 2026, it sits at the center of a much larger health and biotech market. Startups now work on cell repair, age-related disease, health data, smart devices, and new drug targets. At the same time, major investors have put very large sums behind companies that aim to help people live longer and stay healthier.
The scale of this market shows why investors now pay close attention. Longevity biotech companies raised about $3.74 billion across 49 finance deals in the first quarter of 2026, up 56% from the same period a year earlier. The wider longevity sector may reach $8 billion to $9 billion in investment during 2026, based on Dealroom data cited by Vogue Business.
Altos Labs Has Set the Bar
Altos Labs remains one of the biggest names in the field. The company launched in 2022 with $3 billion in fully committed capital. Its work centers on cellular rejuvenation, with the goal of restoring cell health and resilience. Its founders include Hal Barron, Rick Klausner, and Hans Bishop. ARCH Venture Partners was one of its early major backers.
The size of Altos Labs matters because it shows how much trust wealthy investors have placed in basic aging science. The company does not sell a consumer product. Instead, it works on deep biology that may lead to new treatments for disease, injury, and age-related decline.
That makes Altos a long-term bet. Investors do not expect quick results from this type of science. They want a platform that can produce several useful treatments over time. This model has made Altos one of the key companies that other investors use as a reference point.
Retro Biosciences Has a Clear Clinical Goal
Retro Biosciences has also gained major attention. Sam Altman first gave the company $180 million. In 2025, Retro set out to raise a $1 billion Series A to support its work on therapies that may add 10 healthy years to human life. The company has focused on cellular reprogramming, autophagy, and other ways to address age-related disease.
Retro now has a major advantage: it has reached human trials. Its experimental drug RTR-242 is in a Phase 1 safety trial in Australia. The trial tests a treatment that aims to improve the cell’s own recycling system, with a focus on diseases such as Alzheimer’s. In August 2026, Retro expanded the trial from 76 to 108 healthy volunteers after no major safety signal appeared.
For investors, this step is important. Longevity science can look exciting in a lab, but human data is the real test. Retro’s move into clinical work gives investors a chance to judge the science on real patient data rather than only on lab results.
NewLimit Has Built Strong Investor Support
NewLimit has become another major name in cellular reprogramming. In June 2026, the company raised $435 million in a Series C led by Founders Fund. Thrive Capital, Greenoaks, and Quiet Capital joined as new investors. Existing backers included Kleiner Perkins, Nat Friedman and Daniel Gross, Valor Equity Partners, Eli Lilly Ventures, and Human Capital.
The new round brought NewLimit’s total capital to about $682 million, based on current market data. The company plans to take its first aging reprogramming medicine into human clinical trials in 2027. Its work focuses on ways to reverse cell age, with early research showing a prototype medicine could reverse the age of old human liver cells.
The investor mix is also worth note. Founders Fund, Thrive, Eli Lilly Ventures, Kleiner Perkins, and other repeat backers give NewLimit a strong base of capital and industry knowledge. For the wider market, that support suggests that cellular reprogramming has moved from a highly speculative idea toward a serious biotech investment area.
Oura Shows the Consumer Side of Longevity
Not every major longevity company works on drugs. Oura has built a strong position through its smart ring and health platform. In October 2025, Oura raised $900 million in Series E capital. Fidelity Management & Research Company led the round, with support from ICONIQ, Whale Rock, and Atreides. The deal valued Oura at about $11 billion.
Oura gives users data on sleep, heart rate, temperature, activity, and other health measures. Its value to the longevity market comes from a simple idea: people may make better health choices when they have regular data about their bodies.
Oura also shows that longevity is not limited to a future drug. Health devices, software, tests, and preventive care can all form part of the same market. Its scale gives investors another route into the long-term health trend.
BioAge Brings Aging Science to Metabolic Health
BioAge Labs is another company worth close attention. It develops treatments for metabolic disease by targeting the biology of human aging. The company became a public biotech and raised $115 million in an upsized public offer in January 2026. The deal was led by Goldman Sachs, Piper Sandler, and Citigroup.
BioAge also has ties with major drug companies. Its research work with Novartis focuses on new targets at the link between aging biology and exercise. A separate deal with Lilly ExploR&D covers therapeutic antibodies against metabolic aging targets found through its research platform.
This model may appeal to investors who want a more direct route to approved medicine. Rather than treat aging itself as a disease, BioAge uses aging biology to find better ways to treat diseases such as metabolic and cardiovascular conditions.
Insilico Medicine Connects AI With Longevity
Insilico Medicine has taken another route by combining artificial intelligence with drug discovery. Current market data puts its total capital at about $811 million. Its backers include Value Partners, Warburg Pincus, and Prosperity7. The company completed an IPO in 2025, which gave it access to public market capital.
The company matters because AI may reduce the time and cost needed to find new drug candidates. For longevity science, that could be especially useful. Aging involves many biological systems, so tools that help researchers find targets and test compounds faster may have a major role.
What Investors Care About Now
The pattern across these companies is clear. Investors no longer look only at bold claims about longer life. They want strong science, real clinical progress, useful data, and a path to a real product.
NewLimit has attracted repeat support from major venture firms and a large pharmaceutical investor. Retro has reached human trials. BioAge has entered public markets and has drug programs with clear disease targets. Oura has shown that consumers will pay for health data. Altos has the scale and scientific talent for a long-term platform. Insilico adds the power of AI to the drug discovery process.
The market is still risky. Aging is complex, and many ideas that look strong in early research may fail in human trials. The history of longevity biotech includes setbacks, which means large capital alone does not prove that a treatment will work.
The Next Phase of Longevity
The next few years may show which companies can turn strong science into real health benefits. Human trials will matter more. Drug safety data will matter more. Revenue and customer use will matter more for consumer health firms.
For investors, the biggest names are no longer just science projects. They are becoming serious businesses with large capital bases, major partners, clinical plans, and public market access.
That shift explains the close attention around Altos Labs, Retro Biosciences, NewLimit, Oura, BioAge Labs, and Insilico Medicine. Each company takes a different path, but all point to the same larger idea: the future of longevity may come from a mix of better biology, smarter technology, earlier care, and new medicines.
Also Read – Best Marketing Channels for Early-Stage Startups